Incorporação de tecnologias em saúde: a importância do tratamento medicamentoso das cefaleias primárias no sistema único de saúde brasileiro

Views: 463

Autores

DOI:

https://doi.org/10.48208/HeadacheMed.2022.27

Palavras-chave:

Drogas, Dor de cabeça, Saúde pública, Tecnologia, Enxaqueca

Resumo

Incorporação de tecnologias em saúde: a importância do tratamento medicamentoso das cefaleias primárias no sistema único de saúde brasileiro

Downloads

Não há dados estatísticos.

Referências

Schmidt MI, Duncan BB, e Silva GA, Menezes AM, Monteiro CA, Barreto SM, . . . Menezes PR. Chronic non-communicable diseases in Brazil: burden and current challenges. The Lancet 2011;377(9781):1949-1961 Doi: 10.1016/s0140-6736(11)60135-9 DOI: https://doi.org/10.1016/S0140-6736(11)60135-9

Souza MNP, Cohen JM, Piha T, Ribalov R, Lengil T, van der Laan A, . . . Lee LK. Burden of migraine in Brazil: A cross‐sectional real‐world study. Headache: The Journal of Head and Face Pain 2022;62(10):1302-1311 Doi: 10.1111/head.14413 DOI: https://doi.org/10.1111/head.14413

Peres MFP, Queiroz LP, Rocha-Filho PS, Sarmento EM, Katsarava Z and Steiner TJ. Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. The Journal of Headache and Pain 2019;20(1):Doi: 10.1186/s10194-019-1036-6

Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA and Zukerman E. A Nationwide Population-Based Study of Migraine in Brazil. Cephalalgia 2009;29(6):642-649 Doi: 10.1111/j.1468-2982.2008.01782.x

De Souza Silva M, Esther da Silva Alves G, Thiago de Lima Silva J, Flaudiano Bem Leite A and Roberta Ribeiro dos Santos E. Internações por enxaqueca. Jornal Memorial da Medicina 2020;1(2):57-65 Doi: 10.37085/jmmv1.n2.2019.pp.57-65 DOI: https://doi.org/10.37085/jmmv1.n2.2019.pp.57-65

Krymchantowski A, Jevoux C, Silva-Neto RP and Krymchantowski AG. Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions. Headache 2020;60(10):2413-2420 Doi: 10.1111/head.13999 DOI: https://doi.org/10.1111/head.13999

Peres MFP, Queiroz LP, Rocha-Filho PS, Sarmento EM, Katsarava Z and Steiner TJ. Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. J Headache Pain 2019;20(1):85 Doi: 10.1186/s10194-019-1036-6 DOI: https://doi.org/10.1186/s10194-019-1036-6

Queiroz LP, Peres MF, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA and Zukerman E. A nationwide population-based study of migraine in Brazil. Cephalalgia 2009;29(6):642-649 Doi: 10.1111/j.1468-2982.2008.01782.x DOI: https://doi.org/10.1111/j.1468-2982.2008.01782.x

Domingues RB, Aquino CC, Santos JG, da Silva AL and Kuster GW. Prevalence and impact of headache and migraine among Pomeranians in Espirito Santo, Brazil. Arq Neuropsiquiatr 2006;64(4):954-957 Doi: 10.1590/s0004-282x2006000600013 DOI: https://doi.org/10.1590/S0004-282X2006000600013

Raffaelli E. Migraine awareness, treatment, and education in Brazil. Cephalalgia 1998;18 Suppl 22(67; discussion 67-68 Doi: 10.1177/0333102498018s2213 DOI: https://doi.org/10.1177/0333102498018S2213

Nichols V, Pearce G, Ellard DR, Evans S, Haywood K, Norman C, . . . team C. Patient and public involvement in a UK National Institute for Health Research Programme Grant for Applied Research: experiences from the Chronic Headache Education and Self-management Study (CHESS). Prim Health Care Res Dev 2021;22:e72 Doi: 10.1017/S1463423621000670 DOI: https://doi.org/10.1017/S1463423621000670

Charleston Lt and Evans RW. Public policy and headache: observations of health care policy in the US congress from a legislative fellow's perspective. Headache 2013;53(5):827-830 Doi: 10.1111/head.12098 DOI: https://doi.org/10.1111/head.12098

Steiner TJ. Headache in the world: public health and research priorities. Expert Rev Pharmacoecon Outcomes Res 2013;13(1):51-57 Doi: 10.1586/erp.12.78 DOI: https://doi.org/10.1586/erp.12.78

Ziegler DK. Headache. Public health problem. Neurol Clin 1990;8(4):781-791 DOI: https://doi.org/10.1016/S0733-8619(18)30316-5

Kowacs F, Roesler CAdP, Piovesan ÉJ, Sarmento EM, Campos HCd, Maciel Jr JA, . . . Jurno ME. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos de Neuro-Psiquiatria 2019;77(7):509-520 Doi: 10.1590/0004-282x20190078 DOI: https://doi.org/10.1590/0004-282x20190078

Relação Nacional de Medicamentos Essenciais Rename 2022 [recurso eletrônico] / Ministério da Saúde, Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde, Departamento de Assistência Farmacêutica e Insumos Estratégicos. – Brasília : Ministério da Saúde, 2022. 181 p. : il.

Silberstein SD and Edvinsson L. Is CGRP a marker for chronic migraine? Neurology 2013;81(14):1184-1185 Doi: 10.1212/WNL.0b013e3182a6cc33 DOI: https://doi.org/10.1212/WNL.0b013e3182a6cc33

Aggarwal M, Puri V and Puri S. Serotonin and CGRP in migraine. Ann Neurosci 2012;19(2):88-94 Doi: 10.5214/ans.0972.7531.12190210 DOI: https://doi.org/10.5214/ans.0972.7531.12190210

Salvatore CA and Kane SA. CGRP receptor antagonists: toward a novel migraine therapy. Curr Pharm Biotechnol 2011;12(10):1671-1680 Doi: 10.2174/138920111798357401 DOI: https://doi.org/10.2174/138920111798357401

Tvedskov JF, Tfelt-Hansen P, Petersen KA, Jensen LT and Olesen J. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine. Cephalalgia 2010;30(11):1346-1353 Doi: 10.1177/0333102410363491 DOI: https://doi.org/10.1177/0333102410363491

Ho TW, Edvinsson L and Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6(10):573-582 Doi: 10.1038/nrneurol.2010.127 DOI: https://doi.org/10.1038/nrneurol.2010.127

Schelstraete C and Paemeleire K. CGRP antagonists: hope for a new era in acute migraine treatment. Acta Neurol Belg 2009;109(4):252-261

Tfelt-Hansen P and Ashina M. CGRP in migraine. J Headache Pain 2009;10(5):385; author reply 387-388 Doi: 10.1007/s10194-009-0139-x DOI: https://doi.org/10.1007/s10194-009-0141-3

Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 2008;155(7):967-969 Doi: 10.1038/bjp.2008.346 DOI: https://doi.org/10.1038/bjp.2008.346

Durham PL. CGRP receptor antagonists: a new choice for acute treatment of migraine? Curr Opin Investig Drugs 2004;5(7):731-735

Brain SD, Poyner DR and Hill RG. CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine? Trends Pharmacol Sci 2002;23(2):51-53 Doi: 10.1016/s0165-6147(02)01945-4 DOI: https://doi.org/10.1016/S0165-6147(02)01945-4

Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs 2001;2(9):1261-1268

Autunno M, Messina C, Blandino A and Rodolico C. Hypnic headache responsive to low-dose topiramate: a case report. Headache 2008;48(2):292-294 Doi: 10.1111/j.1526-4610.2007.01000.x DOI: https://doi.org/10.1111/j.1526-4610.2007.01000.x

Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ and Group T-M-S. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814-823 Doi: 10.1111/j.1468-2982.2007.01326.x DOI: https://doi.org/10.1111/j.1468-2982.2007.01326.x

Palacio E, Rodero L and Pascual J. Topiramate-responsive headache due to idiopathic intracranial hypertension in Behcet syndrome. Headache 2004;44(5):436-437 Doi: 10.1111/j.1526-4610.2004.04095.x DOI: https://doi.org/10.1111/j.1526-4610.2004.04095.x

Leone M, Dodick D, Rigamonti A, D'Amico D, Grazzi L, Mea E and Bussone G. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003;23(10):1001-1002 Doi: 10.1046/j.1468-2982.2003.00665.x DOI: https://doi.org/10.1046/j.1468-2982.2003.00665.x

McGeeney BE. Topiramate in the treatment of cluster headache. Curr Pain Headache Rep 2003;7(2):135-138 Doi: 10.1007/s11916-003-0023-3 DOI: https://doi.org/10.1007/s11916-003-0023-3

Rapoport AM, Bigal ME, Tepper SJ and Sheftell FD. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 2003;23(1):69-70; author reply 70 Doi: 10.1046/j.1468-2982.2003.00481_1.x DOI: https://doi.org/10.1046/j.1468-2982.2003.00481_1.x

Aschehoug I, Bratbak DF and Tronvik EA. Long-Term Outcome of Patients With Intractable Chronic Cluster Headache Treated With Injection of Onabotulinum Toxin A Toward the Sphenopalatine Ganglion - An Observational Study. Headache 2018;58(10):1519-1529 Doi: 10.1111/head.13398 DOI: https://doi.org/10.1111/head.13398

Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, . . . Torelli P. The use of onabotulinum toxin A (Botox((R))) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurol Sci 2016;37(7):1127-1131 Doi: 10.1007/s10072-016-2568-z DOI: https://doi.org/10.1007/s10072-016-2568-z

Yerry JA, Kuehn D and Finkel AG. Onabotulinum toxin a for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study. Headache 2015;55(3):395-406 Doi: 10.1111/head.12495 DOI: https://doi.org/10.1111/head.12495

Downloads

Publicado

2022-12-31

Como Citar

1.
Godoi AL, Santos ERR dos, Andrade JR. Incorporação de tecnologias em saúde: a importância do tratamento medicamentoso das cefaleias primárias no sistema único de saúde brasileiro. Headache Med [Internet]. 31º de dezembro de 2022 [citado 31º de março de 2025];13(4):233-6. Disponível em: https://headachemedicine.com.br/index.php/hm/article/view/743

Edição

v. 13 n. 4 (2022)

Seção

Editorial

Licença

Copyright (c) 2022 André Luiz Godoi, Erlene Roberta Ribeiro dos Santos, Juliana Ramos Andrade

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Artigos mais lidos pelo mesmo(s) autor(es)

1 2 > >>